Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges
Documentos PDF
Imagenes y Videos
Resumo
Opioid abuse and related overdose deaths continue to rise in the United States, contributing to the current
national opioid crisis. Although several opioid-based pharmacotherapies are available (e.g., methadone, buprenorphine, naloxone), they show limited effectiveness in long-term relapse prevention. In response to the
opioid crisis, the National Institute on Drug Abuse proposed a list of pharmacological targets of highest priority
for medication development for the treatment of opioid use disorders (OUD). Among these are antagonists of
dopamine D3 receptors (D3R). In this review, we first review recent progress in research of the dopamine
hypothesis of opioid reward and abuse and then describe the rationale and recent development of D3R ligands
for the treatment of OUD. Herein, an emphasis is placed on the effectiveness of newly developed D3R antagonists
in the animal models of OUD. These new drug candidates may also potentiate the analgesic effects of clinically
used opioids, making them attractive as adjunctive medications for pain management and treatment of OUD.
Palabras clave
Dopamine D3 receptor; Opioid use disorder; Analgesia; Drug self-administration; Relapse; AddictionLink para o recurso
https://doi.org/10.1016/j.neubiorev.2020.04.024Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.